Multiple aspects of this DNAI1 mRNA therapy need to be considered to determine if a beneficial effect in PCD-affected individuals will be observed, including the amount of rescued ciliary activity required for restoration of coordinated MCC and the tolerability of the dosing regimen to reach this required amount. This evidence concerns the gene DNAI1 and primary ciliary dyskinesia.